Proliferative Effects of Estradiol- or Ethinylestradiol-Progestogen Combinations on Human Breast Cancer Cells in an Intermitted and a Long-term Regimen

Abstract

Currently the use of natural estradiol as estrogenic component in oral contraceptives is more and more extended. It is unknown whether the application of this estrogen is associated with a different breast cancer risk as compared to the common use of the synthetic ethinylestradiol. In addition with the intention to reduce menstruation associated symptoms and bleeding periods an extended-cycle regimen is currently considered. In the present in vitro work, we have compared the effect of these different estrogenic compounds and the different treatment regimens on breast cancer risk. Human breast cancer cells (ZR75-1 and HCC1500) were incubated with equimolar concentrations of estradiol or ethinylestradiol combined with various progestogens, dienogest, drospirenone, keto-desogestrel, levonorgestrel, and nomegestrel. Usual and extended cycle was mimicked by incubation periods of 3 days with 1 day hormones off and 4 days, respectively. Molecular markers for proliferation and apoptosis were investigated by Western blot. In both cell lines estradiol and ethinylestradiol elicited a significant increase in the proliferation rate without difference between the 2 estrogens. The effect in the long-term cycle tended to be more pronounced than in the intermitted cycle. Progestogen addition most significantly reduced the estrogen-induced proliferation rate. The molecular markers were influenced by the progestogens mostly in the same manner, reducing the proliferation/apoptosis rate. Our results indicate that both estrogenic based combinations with progestogens may not increase breast cancer risk independent from the regimen, intermitted or long-term cycle. However clinical studies are necessary to prove these in vitro results.

Key words

estradiol - ethinylestradiol - progestogens - breast cancer cells - proliferation - continuous incubation - intermitted incubation

• References

• 1 Althuis MD, Brogan DR, Coates RJ, Daling JR, Gammon MD, Malone KE, Schoenberg JB, Brinton LA. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer 2003; 88: 50-57
• 2 Brinton LA, Gammon MD, Malone KE, Schoenberg JB, Daling JR, Coates RJ. Modification of oral contraceptive relationships on breast cancer risk by selected factors among younger women. Contraception 1997; 55: 197-203
• 3 Holmberg L, Lund E, Bergstrom R, Adami HO, Meirik O. Oral contraceptives and prognosis in breast cancer: effects of duration, latency, recency, age at first use and relation to parity and body mass index in young women with breast cancer. Eur J Cancer 1994; 30A: 351-354
• 4 Newcomb PA, Longnecker MP, Storer BE, Mittendorf R, Baron J, Clapp RW, Trentham-Dietz A, Willett WC. Recent oral contraceptive use and risk of breast cancer (United States). Cancer Causes Control 1996; 7: 525-532
• 5 Reeves GK, Patterson J, Vessey MP, Yeates D, Jones L. Hormonal and other factors in relation to survival among breast cancer patients. Int J Cancer 2000; 89: 293-299
• 6 Trivers KF, Gammon MD, Abrahamson PE, Lund MJ, Flagg EW, Moorman PG, Kaufman JS, Cai J, Porter PL, Brinton LA, Eley JW, Coates RJ. Oral contraceptives and survival in breast cancer patients aged 20 to 54 years. Cancer Epidemiol Biomarkers Prev 2007; 16: 1822-1827
• 7 Collaborative Group on Hormonal Factors in Breast Cancer . Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 1996; 347: 1713-1727
• 8 Vessey M, Yeates D, Flynn S. Factors affecting mortality in a large cohort study with special reference to oral contraceptive use. Contraception 2010; 82: 221-229
• 9 Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2001; 344: 276-285
• 10 Press DJ, Sullivan-Halley J, Ursin G, Deapen D, McDonald JA, Strom BL, Norman SA, Simon MS, Marchbanks PA, Folger SG, Liff JM, Burkman RT, Malone KE, Weiss LK, Spirtas R, Bernstein L. Breast cancer risk and ovariectomy, hysterectomy, and tubal sterilization in the women’s contraceptive and reproductive experiences study. Am J Epidemiol 2011; 173: 38-47
• 11 Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, Manson JE, Stefanick ML, Ockene J, Sarto GE, Johnson KC, Wactawski-Wende J, Ravdin PM, Schenken R, Hendrix SL, Rajkovic A, Rohan TE, Yasmeen S, Prentice RL. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 2010; 304: 1684-1692
• 12 Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids 2011; 76: 636-652
• 13 Zhu Y, Hanna RN, Schaaf MJ, Spaink HP, Thomas P. Candidates for membrane progestin receptors – past approaches and future challenges. Comp Biochem Physiol C Toxicol Pharmacol 2008; 148: 381-389
• 14 Heikinheimo O. Long-cycle combined contraception: less bleeding and increased subject satisfaction. Acta Obstet Gynecol Scand 2006; 85: 517-518
• 15 Wiegratz I, Hommel HH, Zimmermann T, Kuhl H. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives. Contraception 2004; 69: 37-42
• 16 Merki-Feld GS, Seeger H, Mueck AO. Comparison of the proliferative effects of ethinylestradiol on human breast cancer cells in an intermittent and a continuous dosing regime. Horm Metab Res 2008; 40: 206-209
• 17 Lippert C, Seeger H, Wallwiener D, Mueck AO. Comparison of the effects of 17alpha-ethinylestradiol and 17beta-estradiol on the proliferation of human breast cancer cells and human umbilical vein endothelial cells. Clin Exp Obstet Gynecol 2002; 29: 87-90
• 18 Gompel A, Somaï S, Chaouat M, Kazem A, Kloosterboer HJ, Beusman I, Forgez P, Mimoun M, Rostène W. Hormonal regulation of apoptosis in breast cells and tissues. Steroids 2000; 65: 593-598
• 19 Frasor J, Danes JM, Komm B, Chang KC, Lyttle CR, Katzenellenbogen BS. Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 2003; 144: 4562-4574
• 20 Dai J, Jian J, Bosland M, Frenkel K, Bernhardt G, Huang X. Roles of hormone replacement therapy and iron in proliferation of breast epithelial cells with different estrogen and progesterone receptor status. Breast 2008; 17: 172-179
• 21 Chen FP, Chien MH, Chen HY, Ng YT. Effects of different progestogens on human breast tumor cell growth. Climacteric 2011; 14: 345-351
• 22 Hofseth LJ, Raafat AM, Osuch JR, Pathak DR, Slomski CA, Haslam SZ. Hormone replacement therapy with estrogen or estrogen plus medroxyprogesterone acetate is associated with increased epithelial proliferation in the normal postmenopausal breast. J Clin Endocrinol Metab 1999; 84: 4559-4565
• 23 Migliaccio A, Di Domenico M, Castoria G, de Falco A, Bontempo P, Nola E, Auricchio F. Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 1996; 15: 1292-1300
• 24 Ballaré C, Vallejo G, Vicent GP, Saragüeta P, Beato M. Progesterone signaling in breast and endometrium. J Steroid Biochem Mol Biol 2006; 102: 2-10
• 25 Lee KL, Dai Q, Hansen EL, Saner CN, Price TM. Modulation of ATP-induced calcium signaling by progesterone in T47D-Y breast cancer cells. Mol Cell Endocrinol 2010; 319: 109-115
• 26 Sawan C, Herceg Z. Histone modifications and cancer. Adv Genet 2010; 70: 57-85
• 27 Thomas DB, Noonan EA. WHO Collaborative Study of Neoplasia and Steroid Contraceptive . Breast cancer and specific types of combined oral contraceptives. Br J Cancer 1992; 65: 108-113
• 28 UK National Case-Control Study Group . Oral contraceptives and cancer risk in young women. Lancet 1989; 1: 973-982
• 29 Vessey MP, Mc Pherson K, Villard-Mackintosh L, Yeates D. Oral contraceptives and breast cancer: latest findings in a large cohort study. Br J Cancer 1989; 59: 613-617
• 30 Dumeaux V, Alsaker E, Lund E. Breast cancer and specific types of oral contraceptives: A large Norwegian cohort study. In J Cancer 2003; 105: 844-850
• 31 Hunter DJ, Colditz GA, Hankinson SE, Malspeis S, Spiegelman D, Chen W, Stampfer MJ, Willett WC. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev 2010; 19: 2496-2502
• 32 Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000; 62: 29-38
• 33 Zeun S, Lu M, Uddin A, Zeiler B, Morrison D, Blode H. Pharmacokinetics of an oral contraceptive containing oestradiol valerate and dienogest. Eur J Contraception Reprod Health Care 2009; 14: 221-232
• 34 Writing Group for the Women’s Health Initiative Investigators . Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321-333
• 35 Neubauer H, Yang Y, Seeger H, Fehm T, Cahill MA, Tong X, Ruan X, Mueck AO. The presence of a membrane-bound progesterone receptor sensitizes the estradiol-induced effect on the proliferation of human breast cancer cells. Menopause 2011; 18: 845-850